0001209191-20-055051.txt : 20201016 0001209191-20-055051.hdr.sgml : 20201016 20201016160436 ACCESSION NUMBER: 0001209191-20-055051 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201015 FILED AS OF DATE: 20201016 DATE AS OF CHANGE: 20201016 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Neumann Mark CENTRAL INDEX KEY: 0001756211 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36274 FILM NUMBER: 201244029 MAIL ADDRESS: STREET 1: C/O INTRA-CELLULAR THERAPIES, INC. STREET 2: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc. CENTRAL INDEX KEY: 0001567514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 364742850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 212-923-3344 MAIL ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: Oneida Resources Corp. DATE OF NAME CHANGE: 20130122 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-10-15 0 0001567514 Intra-Cellular Therapies, Inc. ITCI 0001756211 Neumann Mark C/O INTRA-CELLULAR THERAPIES, INC. 430 EAST 29TH STREET NEW YORK NY 10016 0 1 0 0 EVP, Chief Commercial Officer Common Stock 2020-10-15 4 M 0 13448 A 34912 D Common Stock 2020-10-16 4 S 0 6792 26.80 D 28120 D Restricted Stock Units 2020-10-15 4 M 0 13448 0.00 D Common Stock 13448 13448 D Restricted stock units convert into common stock on a one-for-one basis. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2020. The proceeds from these sales will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.36 to $27.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Each restricted stock unit represents a contingent right to receive one share of common stock. The restricted stock units vest as to one third of the shares on October 15, 2019, one third of the shares on October 15, 2020 and one third of the shares on October 15, 2021. /s/ Lawrence J. Hineline, Attorney-in-fact 2020-10-16